References
- Pensato U, Cevoli S, Pierangeli G, Cortelli P. The evolutionary meaning of migraine. Cephalalgia. 2023 Dec;43(12):3331024231209303. doi: 10.1177/03331024231209303.
- Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023 Feb;19(2):109–117. doi: 10.1038/s41582-022-00763-1.
- Estave PM, Beeghly S, Anderson R, Margol C, Shakir M, George G, et al. Learning the full impact of migraine through patient voices: A qualitative study. Headache. 2021 Jul;61(7):1004–1020. doi: 10.1111/head.14151.
- Lotrič Dolinar A, Žvan B, Došenović Bonča P. Productivity losses due to migraine in Slovenia: An analysis of absenteeism and presenteeism costs based on administrative and self-reported data. Zdr Varst. 2020 Apr 6;59(2):75–82. doi: 10.2478/sjph-2020-0010.
- Alwhaibi M, Balkhi B, AlRuthia Y. Anxiety and depression and health-related quality of life among adults with migraine: A national population-based study. Front Public Health. 2023 Oct 4;11:1241800. doi: 10.3389/fpubh.2023.1241800.
- Holdridge A, Buczyner J, Cabret Aymat C, Le A. Prevention of migraine. Semin Neurol. 2022 Oct;42(5):558–570. doi: 10.1055/s-0042-1758781.
- Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. J Headache Pain. 2020 Jul 3;21(1):84. doi: 10.1186/s10194-020-01151-0.
- Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023 Apr;43(4):03331024231159366. doi: 10.1177/03331024231159366.
- Aguilar-Shea AL, Membrilla Md JA, Díaz-de-Terán J. Migraine review for general practice. Aten Primaria. 2022 Feb;54(2):102208. doi: 10.1016/j.aprim.2021.102208.
- Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021 May;28(5):1716–1725. doi: 10.1111/ene.14715.
- Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. 2020 Aug 4;95(5):e469–e479. doi: 10.1212/WNL.0000000000010019.
- Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019 Sep 21;394(10203):1030–1040. doi: 10.1016/S0140-6736(19)31946-4.
- De Luca C, Baldacci F, Mazzucchi S, Lombardo I, Curto L, Ulivi M, et al. CGRP inhibitors and oxidative stress biomarkers in resistant migraine: A real-life study with erenumab, fremanezumab, and galcanezumab. J Clin Med. 2021 Oct 4;10(19):4586. doi: 10.3390/jcm10194586.